Opening stock page...
Fetching company snapshot, pricing, and intelligence.
Opening stock page...
Fetching company snapshot, pricing, and intelligence.
AI confidence 70% · prior close shown (market closed)
BECTON DICKINSON & CO shows stable business momentum based on AlphaOS pipeline evidence, with mixed management execution.
Why it matters: Revenue +5% YoY in Q2 FY2026.
1 signal not yet derived from pipeline evidence
What it means for the thesis — synthesis, not a raw event feed.
Pipeline evidence · 0d ago
BDX's AlphaOS Signals
Upgrade to Pro for validated historical pattern analysis on BDX.
Free accounts see more of this; Premium sees all of it.
Reported figures for BECTON DICKINSON & CO — research only, not investment advice.
Updated
What happened recently for BECTON DICKINSON & CO (BDX) — events, not interpretation.
Research & analysis only — not investment advice.
Held in ETFsweight · est. sleeve dollars
Investment snapshot
BDX's AI investment thesis
Upgrade to Premium for BDX's full multi-agent investment thesis.
Free accounts see more of this; Premium sees all of it.
Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity
Strengthen intelligence
Prior close
$183.82
Market cap
$50.07B
Profitable
No
Revenue $4.71B
Net income
$-311.00M
FY Sep 11, 2026
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Investment Snapshot above is the primary AlphaOS analysis for BECTON DICKINSON & CO — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Follow BECTON DICKINSON & CO through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.
Connected companies and research pages from the AlphaOS knowledge graph.
Structured stock intelligence for companies connected to this research.
Surgical robots, mRNA pipelines, and liquid biopsies are converging—and most investors are still treating them as separate bets.
Breakthroughs in therapies, diagnostics, and digital health are transforming medical outcomes.